Member Info for ShadowCelt

Definitely something brewing here, wouldn't be surprised to see a few large sells come through here as UK catches up

Delayed trade popped up 09:01:44 - £17.35k

What an odd statement to make its going up but thats a bad thing and you can only see it going down.

People are impatient, no reason for such a drop here with plenty of news due.

£5 for sale for 50p !

I completely agree with your reasoning Grace, with both other pharmaceutical giants and tech companies now trying to do the same and playing catchup as i have said before I believe DMTR will be bought out in the not too distant future.

Also as someone working in Software for over 20 years the difference DeepMatter has over other entrants, IBM for example is that this was designed by Chemists and BioChemists. Anyone who has worked in heavy duty software knows it never truly works the other way around ie Software Engineers designing for Chemistry is never going to be close to whats needed as it quite simply isn't their area of expertise.

Exactly, and then stop others competitors currently using it from doing so

This industry is in chaos, expecting carnage across the entire sector well below current levels, no reflection on TUI just the cirumstances

Nice to see multiple RNS roll in, maybe people have written this off too quickly, could be an easy multi bag from here

I cannot stress enough how big a deal it is that ODX does not require deep refrigeration. As a company that makes Temperature Monitoring Equipment for Laboratories, Hospitals and Retail - https://thermonitor.co trust me this is a huge difference both in terms of transportation, storage and distribution.

Oxford has several major advantages over the others. First, it is stable at fridge temperatures of 2-8C, so no worries about freezer boxes containing more than 900 doses having to be used in a hurry or wasted. And for the developing world, it is doubly good news – no freezers needed and fewer doses required due to the initial half-dose.

The Guardian Today newsletter: the headlines, the analysis, the debate – sent direct to you
Read more
Second, the Oxford vaccine is cheap, at £3 a dose, while the other two are more than £20 a dose. Oxford has from the start stressed its ambition to enable the entire world to be vaccinated. It has made arrangements to produce the vaccine around the globe.

Third, the vaccine has a good safety profile, in spite of the hitch some months back when a volunteer in the UK became ill and the trials were paused. And it has been shown to work as well in elderly people – who are most likely to die from Covid – as in other age groups, and with fewer side-effects.

It is great news for the UK government, which has invested heavily in the Oxford vaccine as well as ordering 100m doses. That is enough to immunise the country’s entire adult population. Ease of use – no freezer lorries or storage facilities at -70C – means GP practices can have a fridge-full and take it out to care homes without worrying it will go off. It also makes it possible to visit the frail and elderly in their own homes, so they do not have to be transported to vaccination centres.

Oxford University and AstraZeneca had all trial participants swab themselves at home, allowing it to test whether the vaccine was preventing people from having transmissible coronavirus, or just preventing the virus from making them sick.

Neither Pfizer nor Moderna used methods in their vaccine trials that allow them say for sure if their shots prevent transmission.

Although its trials are still ongoing, early data released Monday by AstraZeneca suggests that the vaccine it developed with Oxford University might in fact prevent viral spread

https://www.dailymail.co.uk/health/article-8982747/Modernas-covid-vaccine-NOT-block-covid-positive-spreading-it.html?adobe_mc=TS%3D1606260413%7CMCAID%3D2EB4240B0531037A-6000019360003483

This is well oversold, massive upside potential from here IMO

https://share-talk.co.uk/announcements/rns/pantheon-resources-plc/notification-of-major-holdings/202011171618496305F

Retrosynthesis was a growing area of the life sciences research and development space, providing an increasing opportunity for ICSYNTH, the board said.

It described ICSYNTH as a “powerful computer-aided synthesis design tool” that enabled chemists to generate synthetic pathways for a target molecule, leading to better, faster and more cost-effective synthesis predictions.

ICSYNTH facilitated innovation by stimulating ideas for alternative or novel synthetic routes that otherwise might not be considered by the chemist, the company claimed.

Development work had recently been completed on a new user interface for the tool, facilitating greater ease of use, with new algorithms introduced to filter out erroneous data from any data source, including proprietary data in electronic laboratory notebooks, which the board said would lead to improved synthesis predictions, resulting in better productivity and time management.

“We are delighted to be supplying our powerful retrosynthesis and forward planning tools to these leaders in their field, expanding our customer base not only in the pharmaceutical industry but also within the agrisciences and contract research organisation sectors,” said chief executive officer Mark Warne.

“With machine learning and cloud technologies both powerful tools in the race to accelerated drug discovery, we see a growing opportunity for both our ICSYNTH and DigitalGlassware™ platforms and look to the future with confidence.”

https://prometheus.org/2020/11/07/shale-plays-fail-to-deliver-look-to-alaska/

Link to Forbes article https://www.forbes.com/sites/arthurberman/2020/10/31/shale-plays-fail-to-deliver-look-to-alaska

https://www.share-talk.com/share-talk-bulletin-board-heroes-monday-26th-october-2020/#gs.j56foc